<a href="https://www.fiercebiotech.com/biotech/boehringer-links-dual-agonist-166-weight-loss-phase-3-leaves-key-questions-unanswered" hreflang="en">Boehringer links dual agonist to 16.6% weight loss in phase 3, but leaves key questions unanswered</a>
Boehringer Ingelheim's dual agonist, survodutide, achieved a 16.6% weight loss in a phase 3 trial, which is competitive but below the efficacy of existing obesity treatments. While the drug shows potential for improving liver health and reducing visceral fat, key questions about its tolerability and overall benefits remain unanswered.
Boehringer Ingelheim's phase 3 trial results for survodutide, a glucagon/GLP-1 dual agonist, suggest potential advantages in targeting cardiometabolic risk and improving liver health, although significant questions remain about its overall efficacy and tolerability. For those tracking healthtech innovations, watch for forthcoming detailed data on its impact on visceral fat and metabolic dysfunction, as well as updates from other ongoing trials that may clarify survodutide's differentiation and competitive positioning in the obesity treatment market.